[go: up one dir, main page]

NO20024429L - Medikamenter for diabeteskomplikasjon og neuropati og anvendelser derav - Google Patents

Medikamenter for diabeteskomplikasjon og neuropati og anvendelser derav

Info

Publication number
NO20024429L
NO20024429L NO20024429A NO20024429A NO20024429L NO 20024429 L NO20024429 L NO 20024429L NO 20024429 A NO20024429 A NO 20024429A NO 20024429 A NO20024429 A NO 20024429A NO 20024429 L NO20024429 L NO 20024429L
Authority
NO
Norway
Prior art keywords
neuropathy
medications
applications
diabetes complication
complication
Prior art date
Application number
NO20024429A
Other languages
English (en)
Norwegian (no)
Other versions
NO20024429D0 (no
Inventor
Yoshiro Kitahara
Kyoko Miura
Original Assignee
Ajinomoto Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Kk filed Critical Ajinomoto Kk
Publication of NO20024429D0 publication Critical patent/NO20024429D0/no
Publication of NO20024429L publication Critical patent/NO20024429L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Botany (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20024429A 2000-03-17 2002-09-16 Medikamenter for diabeteskomplikasjon og neuropati og anvendelser derav NO20024429L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000076542 2000-03-17
PCT/JP2001/002094 WO2001068136A1 (fr) 2000-03-17 2001-03-15 Medicaments permettant de traiter les complications du diabete et des neuropathies et utilisation de ces medicaments

Publications (2)

Publication Number Publication Date
NO20024429D0 NO20024429D0 (no) 2002-09-16
NO20024429L true NO20024429L (no) 2002-11-06

Family

ID=18594265

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024429A NO20024429L (no) 2000-03-17 2002-09-16 Medikamenter for diabeteskomplikasjon og neuropati og anvendelser derav

Country Status (19)

Country Link
US (1) US20030073729A1 (fr)
EP (1) EP1283054A4 (fr)
KR (2) KR20070104953A (fr)
CN (2) CN1234414C (fr)
AU (2) AU2001241168B2 (fr)
BR (1) BR0109336A (fr)
CA (1) CA2403442A1 (fr)
CZ (1) CZ20023121A3 (fr)
HU (1) HUP0300325A3 (fr)
IL (1) IL151690A0 (fr)
MX (1) MXPA02009130A (fr)
NO (1) NO20024429L (fr)
NZ (1) NZ521366A (fr)
PL (1) PL357719A1 (fr)
RU (1) RU2281764C2 (fr)
SK (1) SK14922002A3 (fr)
TW (1) TWI305726B (fr)
WO (1) WO2001068136A1 (fr)
ZA (1) ZA200207223B (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1334962T3 (da) * 2000-10-18 2007-12-10 Ajinomoto Kk Fremgangsmåder til fremstilling af acylphenylalanin
KR100819358B1 (ko) * 2000-10-18 2008-04-04 아지노모토 가부시키가이샤 나테글리니드 결정의 제조방법
PT1334964E (pt) * 2000-10-24 2007-09-20 Ajinomoto Kk Processo para a produção de cristais de nateglinida na forma b
CA2426263C (fr) * 2000-10-24 2010-05-25 Ajinomoto Co., Inc. Preparation contenant du nateglinide
JPWO2002040010A1 (ja) * 2000-10-24 2004-06-03 味の素株式会社 ナテグリニド含有親水性医薬製剤
DE60123665T2 (de) * 2000-12-26 2007-08-16 Sankyo Co., Ltd. Medizinische zusammensetzungen mit diuretischem und die insulinresistenz verbesserndem mittel
JP4433496B2 (ja) * 2002-05-28 2010-03-17 味の素株式会社 Ａｔｐクエン酸リアーゼの発現抑制用医薬組成物及びその使用
US20050096367A1 (en) * 2002-05-28 2005-05-05 Yoshiro Kitahara Pharmaceutical composition for suppression of the expression of ATP citrate lyase and use thereof
JPWO2004002473A1 (ja) * 2002-06-28 2005-10-27 キッセイ薬品工業株式会社 血糖コントロール用医薬組成物
KR100709531B1 (ko) * 2002-06-28 2007-04-23 깃세이 야쿠힌 고교 가부시키가이샤 당뇨병성 합병증의 예방 또는 진전저지용 의약조성물
JPWO2004078741A1 (ja) * 2003-03-03 2006-06-08 三栄源エフ・エフ・アイ株式会社 アディポネクチン発現促進剤
US7611693B2 (en) * 2003-09-17 2009-11-03 Board Of Regents, The Univerisity Of Texas System Mechanism-based targeted pancreatic beta cell imaging and therapy
JPWO2005049006A1 (ja) * 2003-11-21 2007-11-29 味の素株式会社 糖尿病治療剤
CA2568640C (fr) 2004-06-04 2011-08-09 Teva Pharmaceutical Industries Ltd. Composition pharmaceutique contenant de l'irbesartan
TW200626163A (en) * 2004-09-22 2006-08-01 Kureha Corp Agent for treating or preventing diabetic neuropathy
KR20070102694A (ko) * 2005-01-31 2007-10-19 아지노모토 가부시키가이샤 혈당 강하제를 함유하는, 내당능 이상, 경계형 당뇨병,인슐린 저항성 및 고인슐린혈증 개선 또는 치료용 의약조성물
CN1947794B (zh) * 2005-10-16 2010-09-01 安徽省现代中药研究中心 含有磺酰脲类和苯氧酸类化合物的药物组合物
WO2007056387A2 (fr) * 2005-11-07 2007-05-18 Elixir Pharmaceuticals, Inc. Combinaisons de metformine et de mitiglinide
BRPI0911874A2 (pt) * 2008-04-29 2018-05-22 Pharnext composições combinadas para o tratamento da doença de alzheimer e doenças relacionadas com zonisamida e acamprosato
BRPI0914889A2 (pt) * 2008-06-17 2015-11-24 Otsuka Chemical Co Ltd peptídeo glp-1 adicionado de cadeia oligossacarídica
SG175390A1 (en) 2009-04-29 2011-12-29 Amarin Corp Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
WO2010127103A1 (fr) 2009-04-29 2010-11-04 Amarin Pharma, Inc. Composition pharmaceutique stable et ses procédés d'utilisation
SI2443246T1 (en) 2009-06-15 2018-05-31 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
SG10201405994UA (en) 2009-09-23 2014-10-30 Amarin Pharmaceuticals Ie Ltd Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same
IT1398168B1 (it) * 2010-02-16 2013-02-14 Chiesi Farma Spa Uso di ingredienti attivi in combinazione per il trattamento delle complicanze del diabete.
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
EP2646013A4 (fr) 2010-11-29 2014-03-26 Amarin Pharma Inc Composition à faible éructation et méthodes de traitement et/ou de prévention de maladie cardiovasculaire chez un sujet présentant une allergie/hypersensibilité aux poissons
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
WO2013115739A1 (fr) * 2012-01-31 2013-08-08 Mahmut Bilgic Procédé de préparation de formulations contenant du natéglinide et de l'acide lipoïque
US8492426B1 (en) * 2012-07-12 2013-07-23 Anis Ahmad Use of carvedilol for treatment of diabetes mellitus
WO2014074552A2 (fr) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions et procédés pour diminuer les triglycérides sans augmenter les taux de ldl-c chez un sujet traité en même temps par la statine
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
HUE067138T2 (hu) 2018-09-24 2024-10-28 Amarin Pharmaceuticals Ie Ltd Módszerek kardiovaszkuláris események veszélyének csökkentésére egy alanyban
US10357476B1 (en) 2018-10-30 2019-07-23 Anis Ahmad Method for treating coronary artery disease
CN116350616A (zh) 2019-11-12 2023-06-30 阿马里纳药物爱尔兰有限公司 降低心房纤颤和/或心房扑动受试者心血管事件风险的方法
US11986452B2 (en) 2021-04-21 2024-05-21 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES444756A1 (es) * 1975-01-31 1977-08-16 Ciba Geigy Procedimiento para la obtencion de compuestos basicos insa- turados.
JPS5938960B2 (ja) * 1979-10-12 1984-09-20 呉羽化学工業株式会社 アミノ安息香酸エステル誘導体及び該誘導体を含有する医薬
JPS6354321A (ja) * 1985-03-27 1988-03-08 Ajinomoto Co Inc 血糖降下剤
JP2764262B2 (ja) * 1987-08-28 1998-06-11 持田製薬株式会社 ヒダントイン誘導体及びそれを有効成分とする医薬組成物
JP2634450B2 (ja) * 1988-11-11 1997-07-23 株式会社サンギ 糖尿病用薬剤
NO179246C (no) * 1991-11-20 1996-09-04 Sankyo Co Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav
IL113313A (en) * 1994-04-11 1999-09-22 Sankyo Co Heterocyclic compounds and pharmaceutical compositions containing the same
JPH08157462A (ja) * 1994-12-08 1996-06-18 Terumo Corp ジオキソチアゾリジン誘導体及びそれを含有する医薬組成物
IL117208A0 (en) * 1995-02-23 1996-06-18 Nissan Chemical Ind Ltd Indole type thiazolidines
JPH08245602A (ja) * 1995-03-08 1996-09-24 Terumo Corp ジオキソチアゾリジン誘導体及びそれを有効成分とする医薬組成物
JPH0995445A (ja) * 1995-07-24 1997-04-08 Kanegafuchi Chem Ind Co Ltd 脳神経細胞障害に対する治療薬
US6006753A (en) * 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
DE69740161D1 (de) * 1996-11-15 2011-05-12 Ajinomoto Kk Nateglinide-Tablettenzubereitungen
PT1011673E (pt) * 1997-06-13 2001-11-30 Novo Nordisk As Nova posologia para a dmni
WO1999035242A1 (fr) * 1998-01-12 1999-07-15 Betagene, Inc. Milieu de culture de cellules neuroendocrines
US6100300A (en) * 1998-04-28 2000-08-08 Bristol-Myers Squibb Company Metformin formulations and method for treating intermittent claudication employing same
US6559188B1 (en) * 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
CO5200844A1 (es) * 1999-09-17 2002-09-27 Novartis Ag Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes
ES2211454T3 (es) * 1999-09-30 2004-07-16 Pfizer Products Inc. Pirrolilamidas como inhibidores de la colageno fosforilasa.
AU1133901A (en) * 1999-10-08 2001-04-23 Novartis Ag Method of treating metabolic disorders
US6586438B2 (en) * 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
RU2264811C2 (ru) * 1999-12-23 2005-11-27 Новартис Аг Применение гипогликемического агента для лечения нарушенного метаболизма глюкозы
EP1616561B1 (fr) * 1999-12-28 2008-06-25 Ajinomoto Co., Inc. Composition antidiabetique pour administration orale
KR100819358B1 (ko) * 2000-10-18 2008-04-04 아지노모토 가부시키가이샤 나테글리니드 결정의 제조방법
DK1334962T3 (da) * 2000-10-18 2007-12-10 Ajinomoto Kk Fremgangsmåder til fremstilling af acylphenylalanin
CA2426263C (fr) * 2000-10-24 2010-05-25 Ajinomoto Co., Inc. Preparation contenant du nateglinide
PT1334964E (pt) * 2000-10-24 2007-09-20 Ajinomoto Kk Processo para a produção de cristais de nateglinida na forma b
AU2002223500A1 (en) * 2000-11-17 2002-05-27 Novo-Nordisk A/S Glucagon antagonists/inverse agonists
US6652838B2 (en) * 2001-04-05 2003-11-25 Robert E. Weinstein Method for treating diabetes mellitus
US6830759B2 (en) * 2002-06-28 2004-12-14 Ajinomoto Co., Inc. Antidiabetic preparation for oral administration
KR20070102694A (ko) * 2005-01-31 2007-10-19 아지노모토 가부시키가이샤 혈당 강하제를 함유하는, 내당능 이상, 경계형 당뇨병,인슐린 저항성 및 고인슐린혈증 개선 또는 치료용 의약조성물

Also Published As

Publication number Publication date
EP1283054A1 (fr) 2003-02-12
KR20020081459A (ko) 2002-10-26
US20030073729A1 (en) 2003-04-17
CN1418109A (zh) 2003-05-14
HUP0300325A3 (en) 2004-08-30
HUP0300325A2 (hu) 2003-07-28
WO2001068136A1 (fr) 2001-09-20
BR0109336A (pt) 2003-06-24
IL151690A0 (en) 2003-04-10
CN1234414C (zh) 2006-01-04
HK1055674A1 (en) 2004-01-21
RU2281764C2 (ru) 2006-08-20
PL357719A1 (en) 2004-07-26
KR100873585B1 (ko) 2008-12-11
SK14922002A3 (sk) 2003-04-01
ZA200207223B (en) 2003-09-09
TWI305726B (en) 2009-02-01
KR20070104953A (ko) 2007-10-29
AU4116801A (en) 2001-09-24
NZ521366A (en) 2005-07-29
NO20024429D0 (no) 2002-09-16
CN1768735A (zh) 2006-05-10
CZ20023121A3 (cs) 2003-05-14
MXPA02009130A (es) 2003-03-12
CA2403442A1 (fr) 2002-09-17
AU2001241168B2 (en) 2005-06-16
EP1283054A4 (fr) 2006-04-12

Similar Documents

Publication Publication Date Title
NO20024429D0 (no) Medikamenter for diabeteskomplikasjon og neuropati og anvendelser derav
DK1390389T3 (da) Cripto-blokerende antistoffer og anvendelser deraf
DK1278763T3 (da) 3-Nitrogen-6,7-dioxygensteroider og anvendelser relateret dertil
NO20034405D0 (no) Anti-ostepontin-antistoff og anvendelse derav
EP1348711A4 (fr) Element luminescent et afficheur
DK2418220T3 (da) Interferon-alpha-antistoffer og anvendelser deraf
NO20043733L (no) Aryl-5-tio-Β-D-glukopyranosid-derivater og legemidler for diabetes inneholdende de samme
DK1400518T3 (da) Heterocycliske forbindelser og lægemidler
NO20011216D0 (no) Azetidinderivater, fremstilling og medisiner inneholdende disse
DE60134026D1 (de) Bildanzeigeelement und bildanzeigeeinrichtung
NO20003967D0 (no) Farmasøytiske preparater
DE60105922D1 (de) Tragbares, autarkes Medikamenteninfusionsgerät
NL1026030A1 (nl) Cannabino¤dreceptorliganden en toepassingen daarvan.
EP1298180A4 (fr) Composition hydrofuge et oleofuge
NO20025656L (no) Opplöselige CTLA4 mutantmolekyler og anvendelser derav
NO20044192L (no) 17alfa-alkyl-17beta-oksy-ostratriener og farmasoytiske preparater
BRPI0013439B8 (pt) composiÇço compreendendo tramadol e um fÁrmaco anticonvulsivante.
DE69932023D1 (de) Piezoelektrisches Leuchtelement, elektronische Anzeigevorrichtung und dessen Herstellungsverfahren
DE60034791D1 (de) Mikrobauelement und dessen herstellungsverfahren
EE200200626A (et) Antraniilamiidid ja nende kasutamine ravimitena
FI20002888L (fi) Numeron siirrettävyys ja numerovälin omistajan tietoa hyödyntävät palvelut
EP1299337A4 (fr) Hydroxyphenstatine et promedicaments associes
EP1416467A4 (fr) Procede d'excitation d'affichage, element d'affichage et affichage
DK1331972T3 (da) Farmaceutiske præparater
EE200400080A (et) Stendid

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application